Dublin, April 16, 2025 (GLOBE NEWSWIRE) -- The "Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2025" report has been added to ResearchAndMarkets.com's offering. Asset Purchase ...

Work continues on a consortium that would be part of an asset purchase agreement to acquire ... that is going to stop our work in moving forward to try to keep these hospitals open,” she said.

Hess has transformed into a focused E&P company, with significant assets ... policy (3-4% versus the previous 1.3%) and the liquidity of Chevron shares. The synergy from the merger promises ...

The company’s board has directed management to start winding down activities while exploring options to monetize assets and ... Inc. announced a reverse triangular merger with QumulusAI, an ...

Something Asset Allocator has written about extensively is whether model portfolios and multi-asset funds compete or coexist. Nextwealth data shows almost 80 per cent of financial advisers who use ...

The most fundamental are typically (1) using machine time to train the model versus using expert modeler time to craft the model and (2) the robustness of the resulting model in the face of data ...

This strategic shift includes a focus on monetizing the company’s assets and intellectual property as well as seeking out-licensing opportunities. The company’s forward-looking statements ...

PARIS: European aerospace companies Airbus, Thales and Leonardo have started preliminary talks with European Union antitrust regulators over a possible merger of their satellite businesses ...

The company’s board has directed management to start winding down activities while exploring options to monetize assets and seek out-licensing ... Inc. announced a reverse triangular merger with ...

Kroger is denying Albertsons’ claims that it didn’t do enough to ensure regulatory approval of the companies’ planned supermarket merger. In court papers filed Tuesday in the Delaware Court ...

(RTTNews) - Eyenovia, Inc. (EYEN) has signed a non-binding letter of intent for a potential reverse merger with Betaliq, Inc., a clinical-stage pharmaceutical company focused on glaucoma treatments.